University of Colorado, Denver
This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.
This is a phase II, single center, prospective, unblinded, immunogenicity and safety study. It is anticipated that enrollment will take approximately 6 months. Duration of participation for study subjects is approximately 1 year. During this interval, participants will continue to receive clinical care from the BMT center, which will ensure retention. Participants will be recruited at their routine clinic visits, which take place every 6 months post-transplantation, or will be recruited by phone. Participants will be consented by study personnel in coordination with the BMT health care provid…
Inclusion Criteria: * Allo-SCT recipients being age 18 - 79 years at time of allo-SCT. * Written informed consent being obtained from the subject * Two doses of RZV, separated by 2 to 6 months, administered at least 1 year after allo-SCT. * Enrollment at \>/= 18 months after second dose of Shingrix. * Female subjects of childbearing potential (FOCBP) enrolled in the study only if they: * have practiced adequate contraception for 30 days prior to vaccination with any dose of zoster vaccine and * have a negative pregnancy test on the day of each dose of zoster vaccine and * agree to cont…
Injection
Arctuva estimate
Verify or correct the compensation shown for this listing.